Cimaterol
CAS : 54239-37-1
Ref. TM-T19769
1mg | Arrêté | ||
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté | ||
1ml*10 (DMSO) | Arrêté |
Informations sur le produit
- CL 263780
- (+-)-5-(1-Hydroxy-2-(isopropylamino)ethyl)anthranilonitrile
- 2-Amino-5-[1-Hydroxy-2-(Propan-2-Ylamino)Ethyl]Benzonitrile
- 2-Amino-5-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]benzonitrile
- 2-Amino-5-[1-hydroxy-2-[(propan-2-yl)amino]ethyl]benzonitrile
- Ab-A 663
- Ac 263,780
- Benzonitrile, 2-amino-5-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (+-)-
- Cimaterol [USAN:INN]
- Cimaterolum
- Voir d'autres synonymes
- Cimaterolum [Latin]
- Cl 263780
- Unii-Zpy8Vrf0Gb
Cimaterol is a potent β-adrenoceptor agonist. cimaterol binds to the L6β-receptor with a Kd value of 26 nM, which is consistent with its EC50 for stimulating protein synthesis (~5 nM). Cimaterol induced muscle hypertrophy and altered endocrine status in lambs, causing a rapid increase in muscle RNA and protein proliferation without concomitant incorporation into satellite cell nuclei. oral administration of Cimaterol decreased plasma insulin and insulin-like growth factor-1 (IGF-1) concentrations in lambs.